EHI
HOWL icon

Eagle Health Investments’s Werewolf Therapeutics HOWL Stock Holding History

Eagle Health Investments’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-700,000
Closed -$1.48M – 22
2024
Q3 		$1.48M Hold
700,000
– – 0.28% 23
2024
Q2 		$1.71M Hold
700,000
– – 0.3% 24
2024
Q1 		$4.54M Buy
+700,000
New +$4.08M 0.84% 24

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Eagle Health Investments's HOWL Position: Q4 2024 in Review

Eagle Health Investments sold out of Werewolf Therapeutics (HOWL) in Q4 2024, closing a stake of 700,000 shares — an estimated $1.48M sold.

Eagle Health Investments first reported a position in HOWL in Q1 2024 and held it in 3 quarters. The position peaked at $4.54M in Q1 2024. 73 funds tracked by Wall St. Rank hold HOWL as of Q4 2024.

  • Eagle Health Investments reported no remaining Werewolf Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Eagle Health Investments sold 700,000 Werewolf Therapeutics shares in Q4 2024, an estimated $1.48M.
  • Eagle Health Investments first reported a position in Werewolf Therapeutics in Q1 2024 and held it in 3 quarters.
  • Eagle Health Investments's Werewolf Therapeutics position peaked at $4.54M in Q1 2024.
  • 73 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q4 2024.

Based on Eagle Health Investments's 13F filing for Q4 2024, filed 12 Feb 2025.